Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression. These medicines are designed to modulate the chromatin regulatory system, which functions to orchestrate the genes our cells express — as well as when, where, and in what order.

Using our Gene Traffic Control® proprietary platform, we are rapidly advancing almost 10 programs across a wide range of cancers — and aim to explore treatments for other diseases. Our lead product candidate is currently in clinical development.